Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
暂无分享，去创建一个
G. Shapiro | F. Meric-Bernstam | J. Infante | D. Hong | L. Walensky | U. Steidl | D. A. Annis | S. Goel | M. Aivado | G. Falchook | M. Saleh | R. Conry | Judy S. Wang | K. Chung | V. Guerlavais | M. Patel | M. Payton | Manish R Patel | M. Saleh | Judy Sing-Zan Wang | David S Hong | Ki Y Chung